Korede Abdullah in Lagos
CHI Pharmaceuticals Limited has reaffirmed its dedication to combating malaria, as Nigeria continues to bear nearly one-third of the global burden of the disease.
Speaking at the World Malaria Day event in Lagos organized by the National Association of Patent and Proprietary Medicine Dealers (NAPPMED) on Thursday, Chief Operating Officer Shriram Iyer stated, “Malaria continues to be a grave health challenge in Nigeria.”
He emphasized the importance of community-based healthcare, highlighting Patent and Proprietary Medicine Vendors as “crucial to ensuring the safety of Nigerians.”
The event, themed ‘Malaria Ends With Us: Re-invent, Re-imagine and Re-ignite’, served as a platform for CHI Pharma to advocate for education, timely access to effective treatment, and the elimination of substandard drugs.
Iyer warned about the dangers of counterfeit medications, referencing recent drug market closures, and introduced CHI’s mass media campaign to rebuild public trust in quality medicines.
“As a responsible healthcare provider,” he said, “we believe that educating consumers and engaging fellow healthcare professionals across the value chain is key to reducing this burden and saving lives.”
As part of its efforts, CHI Pharmaceuticals unveiled the relaunch of Co-Mal, its antimalarial drug designed to treat uncomplicated malaria.
Iyer described the product as a vital tool in the company’s broader strategy to improve healthcare delivery. He also pledged to deepen collaboration with NAPPMED and support ongoing grassroots initiatives.
The company, a member of the TGI Group, continues to play a pivotal role in advancing access to safe and affordable medicines across Nigeria.
